Lupin launches generic Lodosyn tablets in US for Parkinson's disease

Topics Lupin Pharma

Drug firm Lupin on Monday said it has launched its Carbidopa tablets, used for the treatment of symptoms of Parkinson's disease and parkinsonism, in the American market.

The company has launched the product in the strength of 25 mg after approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.

The product is the generic version of Aton Pharma Inc's Lodosyn tablets in the same strength, it added.

The tablets are indicated for use "with Carbidopa-Levodopa or with Levodopa in the treatment of the symptoms of idiopathic Parkinson's disease, postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication," Lupin said.

As per IQVIA MAT January 2018 data, Carbidopa tablets, 25 mg, had annual sales of approximately $17.4 million in the US, Lupin said.

Shares of Lupin were trading at Rs 740.55 per scrip on BSE, up 0.65 per cent from the previous close.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel